Search

Displaying results 7571 - 7580 of 10000 in total
  1. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: Pkr-in-1
  2. Drug

    Molibresib

    go.drugbank.com/drugs/DB16239
    Investigational

    Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects

    Categories: Heterocyclic Compounds, 2-Ring
  3. Drug

    TBA-7371

    go.drugbank.com/drugs/DB16243
    Investigational

    TBA-7371 is under investigation in clinical trial NCT04176250 (Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis).

  4. Drug

    Nanoparticle Epirubicin

    go.drugbank.com/drugs/DB16248
    Investigational

    It is a novel [epirubicin] drug-conjugated polymeric micelle. … Nanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma).

  5. Drug

    Nevanimibe

    go.drugbank.com/drugs/DB16254
    Investigational

    Nevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome).

  6. Drug

    Nidufexor

    go.drugbank.com/drugs/DB16255
    Investigational

    Nidufexor is under investigation in clinical trial NCT03804879 (Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy).

  7. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    Nipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker used to treat certain antibody-mediated autoimmune diseases. … [L64042] It is an aglycosylated, fully human IgG1 monoclonal antibody that binds FcRn and blocks the receptor's recycling of immunoglobulin G (IgG), thereby lowering circulating IgG levels, including pathogenic

    Synonyms: .-1 chain), disulfide with human monoclonal m281 .lambda.-chain, dimer, FCGRT (Fc fragment of IgG receptor and transporter, neonatal Fc receptor, FcRn, transmembrane alpha chain of the neonatal receptor)], Homo sapiens monoclonal antibody (gamma1 heavy chain Homo sapiens (1-
  8. Drug

    Nolasiban

    go.drugbank.com/drugs/DB16259
    Investigational

    Nolasiban is under investigation in clinical trial NCT03081208 (Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI).

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    Olacaftor

    go.drugbank.com/drugs/DB16262
    Investigational

    Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).

  10. Drug

    Olaparib-bodipy FL

    go.drugbank.com/drugs/DB16263
    Investigational

    Olaparib-bodipy FL is under investigation in clinical trial NCT03085147 (A Dye for the Detection of Cancer of the Tongue and Mouth).